Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

October 19, 2021

Heloisa P. Soares, MD, PhD, discusses advances in the management of pancreatic neuroendocrine tumors.

October 12, 2021

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.

October 07, 2021

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

October 06, 2021

Neeraj Agarwal, MD, discusses the adverse effects associated with belzutifan in patients with renal cell carcinoma.

October 03, 2021

Heloisa P. Soares, MD, PhD, discusses recent developments in NETS, pancreatic cancer, and GEJ tumors, as well as sequencing strategies aimed at improving patient outcomes across GI cancers.

September 29, 2021

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

September 23, 2021

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

September 13, 2021

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.

August 24, 2021

Neeraj Agarwal, MD, discusses the efficacy of intensified androgen deprivation therapy in patients with newly diagnosed, metastatic, hormone-sensitive prostate cancer.

August 03, 2021

Sonam Puri, MD, discusses recent research on clinically relevant biomarkers in small cell lung cancer. 

August 02, 2021

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

June 21, 2021

Dr. Masten reflects on the main challenges that arose during the COVID-19 lockdown with regard to surgery in patients with breast cancer, the steps that were taken as the lockdown started to lift, and the changes that have been made with regard to managing patients around the time of surgery and in the operating room.

February 19, 2021

Christos Vaklavas, MD, discusses the progress that has been made in metastatic HR-positive, HER2-negative breast cancer and potential pathways forward for therapeutic sequencing.

January 28, 2021

Cindy B. Matsen, MD, discusses the potential effects of the decrease in screening for patients with breast cancer during the coronavirus disease 2019 pandemic.

January 26, 2021

Neeraj Agarwal, MD, discusses the role of docetaxel in the frontline setting, the emergence of novel hormonal agents in the paradigm, and efforts being made with combination regimens to potentially treat patients with resistant disease.

December 21, 2020

Neeraj Agarwal, MD, discusses remaining challenges with abiraterone acetate in metastatic castration-sensitive prostate cancer.

December 11, 2020

Neeraj Agarwal, MD, remaining challenges in metastatic castration-sensitive prostate cancer.

December 01, 2020

Neeraj Agarwal, MD, discusses unmet needs in metastatic hormone-sensitive prostate cancer.

August 04, 2020

Neeraj Agarwal, MD, discusses the safety profile of olaparib in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer.

May 07, 2020

Neeraj Agarwal, MD, director of the Genitourinary Oncology Program, Oncology Division, professor of medicine, physician, and investigator, at Huntsman Cancer Institute, discusses data with the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with metastatic castration-resistant prostate cancer (mCRPC).